Heparins and cancer survival: Where do we stand?

Thrombosis Research

Volumn 133, Issue SUPPL. 2, 2014, Pages

  Noble, Simon ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Antithrombotics; Cancer; Low molecular weight heparin; Survival; Thromboprophylaxis

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ADVANCED CANCER; ANTICOAGULANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE STUDY; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; THROMBOSIS; VENOUS THROMBOEMBOLISM; BLOOD; MORTALITY; NEOPLASMS;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; NEOPLASMS; THROMBOSIS;

EID: 84901464540     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(14)50023-0     Document Type: Article

References (59)

1. J. Albert-Weil, and J. Nehorias Two cases of neoplasms not justified for classical therapy, treated with intravenous injections of heparin and intramuscular injections of leech extracts Rev Pathol Gen Physiol Clin 54 1954 1014 1020
2. A. Trousseau Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris 2nd ed 1865 The Sydenaham Society Paris, France 654 712
3. G.F. Nash, D.C. Walsh, and A.K. Kakkar The role of the coagulation system in tumour angiogenesis Lancet Oncol 2 2001 608 613 (Pubitemid 33009256)
4. S.A. Mousa Anticoagulants in thrombosis and cancer: the missing link Semin Thromb Hemost 28 2002 45 52 (Pubitemid 34194872)
5. F.R. Rickles, S. Patierno, and P.M. Fernandez Tissue factor, thrombin, and cancer Chest 124 2003 58S 68S (Pubitemid 37128437)
6. L.R. Zacharski, W.G. Henderson, F.R. Rickles, W.B. Forman, C.J. Cornell Jr., and R.J. Forcier et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75 Cancer 53 1984 2046 2052 (Pubitemid 14101772)
7. A.K. Kakkar, M.N. Levine, Z. Kadziola, N.R. Lemoine, V. Low, and H.K. Patel et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) J Clin Oncol 22 2004 1944 1948 (Pubitemid 41095187)
8. A.Y. Lee, F.R. Rickles, J.A. Julian, M. Gent, R.I. Baker, and C. Bowden et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism J Clin Oncol 23 2005 2123 2129 (Pubitemid 46218703)
9. A. Lazo-Langner, G.D. Goss, J.N. Spaans, and M.A. Rodger The effect of low- molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials J Thromb Haemost 5 2007 729 737 (Pubitemid 46563571)
10. E.A. Akl, S. Gunukula, M. Barba, V.E. Yosuico, F.F. Van Doormaal, and S. Kuipers et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation Cochrane Database Syst Rev 2011 CD006652
11. N.M. Kuderer, A.A. Khorana, G.H. Lyman, and C.W. Francis A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications Cancer 110 2007 1149 1161 (Pubitemid 47312882)
12. G.H. Lyman, A.A. Khorana, N.M. Kuderer, A.Y. Lee, J.I. Arcelus, and E.P. Balaban et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 31 2013 2189 2204
13. V.V. Kakkar, C.T. Howe, A.N. Nicolaides, J.T. Renney, and M.B. Clarke Deep vein thrombosis of the leg. Is there a "high risk" group? Am J Surg 120 1970 527 530
14. R.L. Bick Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management Semin Thromb Hemost 5 1978 1 26 (Pubitemid 9038733)
15. S. Noble, and J. Pasi Epidemiology and pathophysiology of cancer-associated thrombosis Br J Cancer 102 Suppl 1 2010 S2 S9
16. N. Levitan, A. Dowlati, S.C. Remick, H.I. Tahsildar, L.D. Sivinski, and R. Beyth et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data Medicine (Baltimore) 78 1999 285 291 (Pubitemid 29439263)
17. M.J. Johnson, M.W. Sproule, and J. Paul The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer Clin Oncol (R Coll Radiol) 11 1999 105 110 (Pubitemid 29259573)
18. J.W. Blom, C.J. Doggen, S. Osanto, and F.R. Rosendaal Malignancies, prothrombotic mutations, and the risk of venous thrombosis JAMA 293 2005 715 722 (Pubitemid 40216041)
19. S. Noble The challenges of managing cancer related venous thromboembolism in the palliative care setting Postgrad Med J 83 2007 671 674 (Pubitemid 350207512)
20. H.T. Sorensen, L. Mellemkjaer, J.H. Olsen, and J.A. Baron Prognosis of cancers associated with venous thromboembolism N Engl J Med 343 2000 1846 1850 (Pubitemid 32104130)
21. R. Hoffman, N. Haim, and B. Brenner Cancer and thrombosis revisited Blood Rev 15 2001 61 67 (Pubitemid 32619559)
22. L. Oleksowicz, N. Bhagwati, and M. DeLeon-Fernandez Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies Cancer Res 59 1999 2244 2250 (Pubitemid 29217692)
23. A.P. Chahinian, K.J. Propert, J.H. Ware, B. Zimmer, M.C. Perry, and V. Hirsh et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B J Clin Oncol 7 1989 993 1002 (Pubitemid 19196521)
24. L.H. Maurer, J.E. Herndon 2nd, D.R. Hollis, J. Aisner, R.W. Carey, and A.T. Skarin et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: A Cancer and Leukemia Group B study J Clin Oncol 15 1997 3378 3387 (Pubitemid 27485858)
25. B. Lebeau, C. Chastang, J.M. Brechot, F. Capron, B. Dautzenberg, and C. Delaisements et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group Cancer 74 1994 38 45 (Pubitemid 24187607)
26. D. Green, R.D. Hull, R. Brant, and G.F. Pineo Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin Lancet 339 1992 1476
27. S. Siragusa, B. Cosmi, F. Piovella, J. Hirsh, and J.S. Ginsberg Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis Am J Med 100 1996 269 277 (Pubitemid 26111623)
28. M.K. Gould, A.D. Dembitzer, R.L. Doyle, T.J. Hastie, and A.M. Garber Low-molecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials Ann Intern Med 130 1999 800 809 (Pubitemid 29231148)
29. C.P. Klerk, S.M. Smorenburg, H.M. Otten, A.W. Lensing, M.H. Prins, and F. Piovella et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy J Clin Oncol 23 2005 2130 2135 (Pubitemid 46218704)
30. K. Sideras, P.L. Schaefer, S.H. Okuno, J.A. Sloan, L. Kutteh, and T.R. Fitch et al. Low- molecular-weight heparin in patients with advanced cancer: A phase 3 clinical trial Mayo Clin Proc 81 2006 758 767 (Pubitemid 43839491)
31. M. Altinbas, H.S. Coskun, O. Er, M. Ozkan, B. Eser, and A. Unal et al. A randomized clinical trial of combination chemotherapy with and without low- molecular-weight heparin in small cell lung cancer J Thromb Haemost 2 2004 1266 1271 (Pubitemid 40186120)
32. E.A. Akl, F.F. Van Doormaal, M. Barba, G. Kamath, S.Y. Kim, and S. Kuipers et al. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: A Cochrane systematic review J Exp Clin Cancer Res 27 2008 4
33. S. Noble Low-molecular-weight heparin and survival in lung cancer Thromb Res 129 Suppl 1 2012 S114 S118
34. G.A. Petralia, N.R. Lemoine, and A.K. Kakkar Mechanisms of disease: the impact of antithrombotic therapy in cancer patients Nat Clin Pract Oncol 2 2005 356 363 (Pubitemid 43118122)
35. I. Ott, E.G. Fischer, Y. Miyagi, B.M. Mueller, and W. Ruf A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280 J Cell Biol 140 1998 1241 1253 (Pubitemid 28128882)
36. X. Wang, M. Wang, M. Amarzguioui, F. Liu, O. Fodstad, and H. Prydz Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice Int J Cancer 112 2004 994 1002 (Pubitemid 39507005)
37. A.K. Kakkar, N.R. Lemoine, M.F. Scully, S. Tebbutt, and R.C. Williamson Tissue factor expression correlates with histological grade in human pancreatic cancer Br J Surg 82 1995 1101 1104
38. A.K. Kakkar, V. Chinswangwatanakul, N.R. Lemoine, S. Tebbutt, and R.C. Williamson Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma Br J Surg 86 1999 890 894 (Pubitemid 29333012)
39. Y. Zhang, Y. Deng, T. Luther, M. Muller, R. Ziegler, and R. Waldherr et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice J Clin Invest 94 1994 1320 1327 (Pubitemid 24286478)
40. J. Contrino, G. Hair, D.L. Kreutzer, and F.R. Rickles In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease Nat Med 2 1996 209 215 (Pubitemid 26054985)
41. R.T. Poon, C.P. Lau, J.W. Ho, W.C. Yu, S.T. Fan, and J. Wong Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma Clin Cancer Res 9 2003 5339 5345 (Pubitemid 37413589)
42. H.H. Versteeg, C.A. Spek, D.J. Richel, and M.P. Peppelenbosch Coagulation factors VIIa and Xa inhibit apoptosis and anoikis Oncogene 23 2004 410 417 (Pubitemid 38174995)
43. D.H. Carney, R. Mann, W.R. Redin, S.D. Pernia, D. Berry, and J.P. Heggers et al. Enhancement of incisional wound healing and neovascularization in normal rats by thrombin and synthetic thrombin receptor-activating peptides J Clin Invest 89 1992 1469 1477
44. G.C. Haralabopoulos, D.S. Grant, H.K. Kleinman, and M.E. Maragoudakis Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo Am J Physiol 273 1997 C239 C245
45. D. Farge, P. Debourdeau, M. Beckers, C. Baglin, R.M. Bauersachs, and B. Brenner et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer J Thromb Haemost 11 2013 56 70
46. C. Kearon, E.A. Akl, A.J. Comerota, P. Prandoni, H. Bounameaux, and S.Z. Goldhaber et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physician Evidence-Based Clinical Practice Guidelines Chest 141 2012 e419S e494S
47. J.A. Heit, M.D. Silverstein, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study Arch Intern Med 160 2000 809 815 (Pubitemid 30165241)
48. A.A. Khorana, N.M. Kuderer, E. Culakova, G.H. Lyman, and C.W. Francis Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 111 2008 4902 4907
49. J. Thaler, C. Ay, and I. Pabinger Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials Thromb Haemost 108 2012 1042 1048
50. G. Agnelli, G. Gussoni, C. Bianchini, M. Verso, M. MandalJ, and L. Cavanna et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study Lancet Oncol 10 2009 943 949
51. S. Noble A step in the right direction, but one size might not fit all Lancet Oncol 10 2009 930 931
52. S.K. Haas, M. Freund, D. Heigener, L. Heilmann, B. Kemkes-Matthes, and G.F. von Tempelhoff et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer Clin Appl Thromb Hemost 18 2012 159 165
53. G. Agnelli, D.J. George, W. Fisher, A.K. Kakkar, M.R. Lassen, and P. Mismetti et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study Clin Oncol suppl; abstr LBA9014 2011
54. H. Riess, B. Opitz, J. Stieler, B. Opitz, T. Scholten, and D. Kauschat-Bruning et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO- 004 trial Clin Oncol 28 2010 abstr 4033
55. A.Y. Lee, M.N. Levine, R.I. Baker, C. Bowden, A.K. Kakkar, and M. Prins et al. Low- molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med. 349 2003 146 153 (Pubitemid 36818784)
56. G.O. Griffiths, S. Burns, S.I. Noble, F.R. Macbeth, D. Cohen, and T.S. Maughan FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer BMC Cancer 9 2009 355
57. M, and D. Knoyle MFNSGGCRRCHKLSMBCDCRL. Preliminary Results From The FRAGMATIC Trial: A Randomised Phase III Clinical Trial Investigating The Effect Of Fragmin. Added To Standard Therapy In Patients With Lung Cancer J Thorac Oncol 8 2013 243
58. G. Meyer, B. Besse, S. Friard, P. Girard, P. Corbi, and R. Azarian et al. Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours Rev Mal Respir 28 2011 654 659
59. A.M. Dingemans, A.J. de Langen, V. Van den Boogaart, J.T. Marcus, W.H. Backes, and H.T. Scholtens et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: A phase II study including molecular imaging Ann Oncol 22 2011 559 566